Oracle's deepening role as TikTok's U.S. data guardian and its aggressive push into regulated AI sectors present a dual narrative of strategic growth and heightened operational scrutiny, following a service outage linked to its infrastructure.
Altria Group expects improved second-half earnings by leveraging a U.S. tobacco tax rebate tied to increased exports, as the Marlboro maker seeks new avenues for growth in a shrinking cigarette market.
Bernstein raises UPS price target to $128, citing robust fourth-quarter results that help balance a softer margin outlook. The logistics giant's strategic pivot away from low-margin Amazon business and ongoing cost-cutting measures shape its 2026 trajectory.
While fully autonomous robotic surgeons remain on the horizon, the foundational technology and data ecosystems being built today are setting the stage for a transformative shift. Two industry giants, Intuitive Surgical and Medtronic, offer investors distinct pathways to capitalize on this evolving landscape.
New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
RBC Capital reaffirms its Outperform rating on UnitedHealth Group, citing management's commitment to long-term earnings targets, even as a lower-than-expected Medicare Advantage rate proposal triggers a sharp sell-off in the health insurer's shares.
As the Federal Reserve signals potential rate cuts, income-focused investors are re-evaluating their portfolios. We analyze seven dividend ETFs that offer resilient income streams and capital appreciation potential when bond yields decline.
With low adoption rates for brokerage 'trusted contacts,' regulators are considering a simple name change to 'emergency contact' to reduce confusion, ease client concerns, and strengthen protections against financial exploitation.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Baidu's flagship AI assistant, Ernie, has surpassed 200 million monthly active users, a milestone reported by the Wall Street Journal. The growth underscores Baidu's deepening integration of AI across its ecosystem amid fierce competition with domestic tech rivals.
While Wall Street analysts are overwhelmingly bullish on several stocks, their optimistic price targets often come with a caveat. We examine one company where the enthusiasm appears justified and two where underlying challenges suggest a more cautious approach.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, they can also mask underlying vulnerabilities. We analyze three such stocks—Figs, Array Technologies, and Kforce—that currently present significant risks to investors, despite their seemingly accessible price tags.
While small-cap stocks can offer overlooked opportunities, their high-risk nature demands careful scrutiny. We examine three companies where valuation and business concerns suggest caution may be warranted.
While stocks priced between $10 and $50 can offer an appealing mix of accessibility and relative maturity, savvy investors know the sticker price is just the beginning. We examine one company in this range that appears poised for growth and two where the fundamentals warrant a closer, more cautious look.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
Valley National Bancorp (VLY) reported fourth-quarter revenue and profit that topped Wall Street forecasts, driven by robust core deposit growth and disciplined balance sheet management. The regional bank's leadership pointed to strategic tech investments and commercial loan demand as key pillars for its 2025 outlook.
While Jabil's stock has mirrored the S&P 500's recent gains, a closer look reveals underlying concerns over growth, profitability, and cash flow. We analyze the risks and spotlight a more compelling alternative in the digital advertising space.
